Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Moist wound dressing for chronic wound treatment now available in Germany
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
The strategic acquisition demonstrates the company’s commitment to increasing OTC consumer convenience in eye care
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Subscribe To Our Newsletter & Stay Updated
